Pandion Shares Trade Up 134% on $1.85 Billion Acquisition by Merck
Source: Streetwise Reports  (2/25/21)
Pandion Therapeutics shares reached a new 52-week high after the company reported it agreed to be acquired by pharmaceutical giant Merck & Co. in an all cash transaction for $60 per share. More >

Nektar Therapeutics Planning Phase 2/3 Studies with Merck and SFJ Pharma for Head and Neck Cancer
Source: Streetwise Reports  (2/17/21)
Nektar Therapeutics shares traded 14% higher after the company reported it plans to conduct a Phase 2/3 study of bempegaldesleukin in combination with Merck's KEYTRUDA® in patients with squamous cell carcinoma of the head and neck and is partnering on a second Phase 2/3 study with SFJ Pharmaceuticals that will provide $150 million to fund development. More >

Pharma Developer Contemplates Adding Lung Scarring as Key Endpoint in Phase 2b/3 COVID-19 Trial
Source: Streetwise Reports  (2/12/21)
Algernon Pharmaceuticals reported it is considering adding "lung scarring" as an additional primary endpoint to its Phase 2b/3 COVID-19 Ifenprodil study protocol. More >

ImmunoGen Shares Rise 30% After Firm Reports FY20 Earnings and 2021 Outlook
Source: Streetwise Reports  (2/12/21)
Shares of ImmunoGen Inc. reached a new 52-week high after the company announced Q4/20 and FY/20 business operating and financial results. More >

AC Immune Reports 'Positive Interim Results' from Novel Phase 1b/2a Alzheimer's Vaccine Trial
Source: Streetwise Reports  (2/11/21)
Shares of AC Immune SA traded 15% higher after the firm reported that interim results from the Phase 1b/2a Alzheimer's trial of its ACI-35.030 vaccine demonstrated generation of potent anti-phospho-Tau antibody responses in 100% of older patients with early Alzheimer's disease. More >

Pharmaceutical Developer Hires Laboratory to Conduct Preclinical Studies of Psychedelic Compound DMT
Source: Streetwise Reports  (2/10/21)
Algernon Pharmaceuticals entered into an agreement with Charles River Laboratories, "a recognized world leader for pre-clinical neurological studies," to conduct preclinical studies for psychedelic compound DMT in stroke patients. More >

Drug Repurposer Ventures into New Area, Use of Psychedelic in Stroke
Source: Streetwise Reports  (2/5/21)
This clinical program of Algernon Pharmaceuticals and upcoming catalysts regarding its in-progress COVID-19 and chronic cough trials are discussed in a Mackie Research Capital Corp. report. More >

Coverage Initiated on Firm Developing Gold Nanoparticle Therapy for Neurological Diseases
Source: Streetwise Reports  (2/5/21)
The reasons Clene is a compelling investment are outlined in a ROTH Capital Partners report. More >

Small-Cap Psychedelic Wellness Company Makes First Acquisition: Ketamine Infusion Centers
Source: Streetwise Reports  (2/4/21)
DELIC aims to become a leader in psychedelic health and wellness clinics. More >

Neurosciences Firm Provides Insight on Recent Alzheimer's/Amyloid Field Developments
Source: Streetwise Reports  (2/3/21)
ProMIS Neurosciences offered its perspective on the latest progress in the Alzheimer's/amyloid field. The firm stated that two recent positive events support the case for PMN310 to be considered "best in class." More >

GW Pharmaceuticals Shares Gain 46% on $7.2 Billion Acquisition by Jazz Pharmaceuticals
Source: Streetwise Reports  (2/3/21)
Shares of GW Pharmaceuticals reached a new 52-week high after the company reported it agreed to be acquired by Jazz Pharmaceuticals in a combination cash and stock deal for $220.00 per share. More >

Cassava Shares Triple After Interim Trial Data Shows Simufilam Improves Cognition and Behavior in Alzheimer's Disease
Source: Streetwise Reports  (2/2/21)
Shares of Cassava Sciences traded 207% higher after the firm provided an interim analysis from an ongoing study demonstrating that simufilam improves cognition and behavior in mild-to-moderate Alzheimer's disease patients. More >

Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT, the 'Spirit Molecule'
Source: Streetwise Reports  (2/1/21)
Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, announced that it has established a clinical research program for the treatment of stroke focused on AP-188 (DMT), a known psychedelic compound. Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021. More >

Viela Bio Shares Rise 52% on $3.05 Billion Buyout by Horizon Therapeutics
Source: Streetwise Reports  (2/1/21)
Shares of Viela Bio traded higher after it was announced that the company entered into a definitive agreement to be acquired by Horizon Therapeutics for $53.00 per share. More >

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports  (1/29/21)
Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial. More >

Coverage Initiated on Biotech 'Improving Drugs Via Prodrug'
Source: Streetwise Reports  (1/27/21)
KemPharm's key near-term catalyst, lead value driver and other pipeline drug candidates are discussed in a ROTH Capital Partners report. More >

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports  (1/27/21)
Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSCâ„¢ Study for treatment of hospitalized ICU COVID-19 patients. More >

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports  (1/26/21)
Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen. More >

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports  (1/25/21)
Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNISâ„¢ (voclosporin) for use in treating adults with active lupus nephritis. More >

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports  (1/22/21)
AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. More >

Biotech Given Go-Ahead to Proceed with Phase 3 COVID-19 Study
Source: Streetwise Reports  (1/20/21)
Algernon Pharmaceuticals reported that it has been granted approval from the Data and Safety Monitoring Board to conduct a Phase 3 Study of Ifenprodil for SARS-CoV-2. More >

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports  (1/20/21)
Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2. More >

Life Sciences Firm Partners with University to Develop Biosynthetic Psilocybin
Source: Streetwise Reports  (1/19/21)
Revive Therapeutics entered into a research agreement with North Carolina State University to develop psilocybin utilizing a natural biosynthesis enzymatic platform. More >

Aclaris Shares Triple in Value on Positive Topline Data from Phase 2a Rheumatoid Arthritis Trial
Source: Streetwise Reports  (1/19/21)
Shares of Aclaris Therapeutics Inc. soared to a new 52-week high after the company reported positive preliminary topline data from its Phase 2a trial of oral ATI-450 for moderate to severe rheumatoid arthritis. More >

Neurosciences Firm Outlines Strategic Priorities for 2021
Source: Streetwise Reports  (1/15/21)
ProMIS Neurosciences discusses its four priority areas in 2021. More >